https://scholars.lib.ntu.edu.tw/handle/123456789/504038
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | YUNG-LI YANG | en_US |
dc.contributor.author | Lin D.-T. | en_US |
dc.contributor.author | Chang S.-K. | en_US |
dc.contributor.author | Lin S.-R. | en_US |
dc.contributor.author | SHU-WHA LIN | en_US |
dc.contributor.author | Chiou R.-J. | en_US |
dc.contributor.author | Yen C.-T. | en_US |
dc.contributor.author | Lin K.-H. | en_US |
dc.contributor.author | SHIANN-TANG JOU | en_US |
dc.contributor.author | MENG-YAO LU | en_US |
dc.contributor.author | HSIU-HAO CHANG | en_US |
dc.contributor.author | Chang W.-H. | en_US |
dc.contributor.author | Lin K.-S. | en_US |
dc.contributor.author | CHUNG-YI HU | en_US |
dc.creator | Yang Y.-L.;Lin D.-T.;Chang S.-K.;Lin S.-R.;Shu-Wha Lin;Chiou R.-J.;Yen C.-T.;Lin K.-H.;Jou S.-T.;Lu M.-Y.;Chang H.-H.;Chang W.-H.;Lin K.-S.;Hu C.-Y. | - |
dc.date.accessioned | 2020-06-22T07:37:12Z | - |
dc.date.available | 2020-06-22T07:37:12Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 1545-5009 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/504038 | - |
dc.description.abstract | Objectives. This retrospective study evaluates the role of pharmacogenomic determinants in the treatment of childhood acute lymphoblastic leukemia (ALL) in the Taiwanese population. Methods. A total of 105 childhood ALL patients received combined chemotherapy of different intensities based on risk-directed Taiwan Pediatric Oncology Group (TPOG)-ALL-93 protocols. Seventeen genetic polymorphisms in 13 pharmacogenomic targets were analyzed by PCR-based restriction fragment length polymorphism (RFLP) and sequence-specific oligonucleotide (SSO) probe hybridization. Pharmacogenomic polymorphisms were correlated with event-free survival (EFS) of patients, with confounding effects adjusted by multivariate regression. Results. Three polymorphic alleles in the multi-drug resistance 1 (MDR1) ABCB1 gene, and homozygotic MDR1 2677GG, 3435CC, and 2677G-3435C genotypes were highly associated with a significant reduction in EFS in those patients treated by the standard risk (SR) protocol (TPOG-ALL-93-SR). The hazard ratios were 6.8 (p=0.01), 21.7 (p=0.009), and 6.8 (p=0.01), respectively. Conclusions. Independent pharmacogenomic determinants associated with treatment outcome were identified in subsets of Taiwanese ALL patients. ? 2009 Wiley-Liss, Inc. | - |
dc.relation.ispartof | Pediatric Blood and Cancer | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | multidrug resistance protein 1; oligonucleotide; acute lymphoblastic leukemia; allele; article; cancer risk; cancer survival; child; childhood leukemia; controlled study; female; genetic polymorphism; genotype; homozygote; human; infant; major clinical study; male; outcome assessment; pharmacogenomics; polymerase chain reaction; preschool child; priority journal; prognosis; restriction fragment length polymorphism; school child; Taiwan; Antineoplastic Combined Chemotherapy Protocols; Asian Continental Ancestry Group; Child; Child, Preschool; Drug Resistance; Female; Humans; Infant; Infant, Newborn; Male; Multivariate Analysis; P-Glycoprotein; Pharmacogenetics; Polymorphism, Genetic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taiwan | - |
dc.title | Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1002/pbc.22292 | - |
dc.identifier.pmid | 19774638 | - |
dc.identifier.scopus | 2-s2.0-74849110305 | - |
dc.relation.pages | 206_211 | - |
dc.relation.journalvolume | 54 | - |
dc.relation.journalissue | 2 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Laboratory Medicine | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.dept | Clinical Laboratory Sciences and Medical Biotechnology | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Clinical Laboratory Sciences and Medical Biotechnology | - |
crisitem.author.orcid | 0000-0002-3598-7218 | - |
crisitem.author.orcid | 0000-0001-6748-5581 | - |
crisitem.author.orcid | 0000-0003-1483-0403 | - |
crisitem.author.orcid | 0000-0003-4461-9967 | - |
crisitem.author.orcid | 0000-0003-1832-8509 | - |
crisitem.author.orcid | 0000-0002-6990-3297 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。